Emerging Therapies in Type 2 Diabetes

Pharmacor -- September 2006

  Introduction:

Type 2 diabetes is one of the most significant public health threats in the world today. In the United States alone, nearly $132 billion in direct and indirect medical costs were attributable to diabetes and its complications. According to the American Diabetes Association, the cost of diabetes will exceed $192 billion in 2020, thereby creating vast market potential for drugs that can reduce this cost burden.

  Questions Answered in This Report:

The type 2 diabetes drug pipeline is among the most active pipelines in the pharmaceutical industry; nearly 400 compounds are in different stages of development. Which are the most promising compounds to emerge from this pipeline and how much market share will they take from current therapies?

GLP-1 analogues and DPP-IV inhibitors that stimulate the incretin pathway (e.g., Amylin’s Byetta LAR, Merck’s Januvia, Novartis’s Galvus) are among the most anticipated drugs in the late-stage pipeline. How do physicians view these agents and what factors will determine which ones will find success in the market?

The first inhaled insulin, Pfizer’s Exubera, launched in the United States and Europe in 2006, and many other inhaled insulins and other formulations of the drug are in development. Which inhaled insulin will succeed Exubera’s early dominance in the market and which formulations of insulin will ultimately control the market in 2020?

  Scope:

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 39 country-specific interviews with thought leaders, diabetes experts, and primary care physicians.

Epidemiology: Prevalence of type 2 diabetes based on criteria established by the American Diabetes Association.

Emerging therapies: We provide a thorough review of the type 2 diabetes pipeline, including coverage of the strengths and weaknesses of pipelines by company and drug class. Our report includes detailed commercial and clinical analyses of 52 individual drugs in 22 current and emerging drug classes.

Market forecast features: Using a top-down approach, we forecast drug sales for current and emerging therapies in type 2 diabetes through 2020.